New Market - January 12, 2026
Novo Nordisk’s Wegovy pill now broadly available across America
Wegovy pill was approved on December 22, 2025 and is used with a reduced calorie diet and increased physical activity for adults with obesity, or with overweight who also have weight-related medical problems, to help them lose weight and keep it off.
Financing - January 12, 2026
EpiEndo completes a EUR 9 million convertible bond issue
The company has raised EUR 5 million of new funding from new and existing investors via a EUR 9 million convertible bond issuance.
Agreement - January 4, 2026
Orexo in agreement with Dexcel to divest US rights to Zubsolv
The company has signed an agreement with Dexcel Pharma USA, to divest the full rights to Zubsolv (buprenorphine/naloxone) sublingual tablet CIII, for the treatment of opioid use disorder, in the US.
Agreement - December 17, 2025
Camurus and Gubra enter agreement
Camurus and Gubra have entered into an exclusive collaboration and license agreement aimed at creating a long-acting therapeutic option for the treatment of hypoparathyroidism.
Acquisition - December 14, 2025
Sobi to acquire Arthrosi Therapeutics
Sobi will pay USD 950 million upfront in cash to acquire Arthrosi, together with up to USD 550 million in cash in clinical, regulatory and sales milestones.
Agreement - December 11, 2025
Nanexa and Moderna enter into license and option agreement
Nanexa will receive an upfront payment of USD 3 million and is entitled to up to USD 500 million in potential milestone payments as well as a tiered single-digit royalty on product sales.
